drugset
drugset / Trial / NCT01914666

An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain

NCT01914666 ↗

Phase 3 Completed 151 enrolled Eli Lilly and Company Shionogi · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the long term safety of duloxetine in participants with Chronic Low Back Pain (CLBP).

Timeline

Start
2013-09
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg Oral

Indications

No indication recorded.